Day: February 15, 2023

(Bergen, 15 February 2023) Mowi recorded record–high revenues of 1,362 million euros in the fourth quarter of 2022. Operational profit was 239 million euros, compared with 146 million euros in the corresponding quarter of 2021. The fourth quarter cemented a record year for Mowi financially. For the first time in its nearly 60-year history the company crossed the one-billion-euro earnings mark with operational profit for the full year reaching 1,005 million euros. Revenue of 4,946 million euros was also a new record for the company. “I would like to express my enormous appreciation to all of my 11,500 colleagues in the organisation without whose dedication and hard work these milestone results would not have been possible,” said Mowi CEO Ivan Vindheim. Mowi harvested 131,000 tonnes in the quarter and a total of 464,000 tonnes in 2022,...

The consolidated sales revenue of Hepsor for the 2022 financial year amounted to 12.9 million euros (including 7.2 million euros in Q4 2022) and the net profit was 1.3 million euros (including a net profit of 1.5 million euros in Q4 2022). In 2022, the Group completed three residential and three commercial property projects. The sales revenue for the financial year has been mainly generated from the sale of completed residential development projects. As of the end of 2022, we have handed over 45 apartments to home buyers in Latvia, including 26 apartments in the 4b Strēlnieku, 18 apartments in the 9 Baložu and 1 apartment in the 24 Āgenskalna development projects, and 40 apartments in the Paevälja Hoovimajade development project in Estonia. The sale of 76 apartments and 1,487 sqm of commercial space in the Priisle Kodu development project...

POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) — via InvestorWire — India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal quarter 2023 financial results. Third Fiscal Quarter 2023 Highlights:The Company expanded the number of sites participating in its Phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer’s disease to a total of four – three in the U. S. and one in Canada. The Company is encouraged by the patient enrollment and interest from many of the leading research centers and has decided to increase the number of trial sites to between 10 and 12 from the originally planned four to five. This will help accelerate the timeline for completion and diversify the patient demographics. The trial will enroll 146 patients, with one...